 The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and physicians choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens including fluoropyrimidine agent, platinum agent, and trastuzumab. 